AlisonSchecterMD
Cardiology • Newton, MAAdjunct Associate Professor, Medicine - Cardiology, Icahn School of Medicine at Mount Sinai
Dr. Schecter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
33 Manor House Road
Newton, MA 02459Phone+1 617-417-8648
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Cardiovascular Disease, 1994 - 1996
Johns Hopkins UniversityResidency, Internal Medicine, 1990 - 1993
State University of New York Downstate Medical Center College of MedicineClass of 1990
Certifications & Licensure
MA State Medical License 2008 - 2026- MA State Medical License 1993 - 2024
Awards, Honors, & Recognition
- Fellow (FCCP) American College Chest Physicians, 2008-2010, 2020
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 86 citationsHuman immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease.Eliseo A. Eugenin, Susan Morgello, Mary E. Klotman, Arevik Mosoian, Patrick A. Lento
The American Journal of Pathology. 2008-04-01 - 148 citationsCCL11 (Eotaxin) Induces CCR3-Dependent Smooth Muscle Cell MigrationRavindra B. Kodali, William J.H. Kim, Irfan I. Galaria, Christine E. Miller, Alison D. Schecter
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004-07-01 - 76 citationsArterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intoleranceRobin P. Choudhury, Jacqueline Birks, Venkatesh Mani, Luca Biasiolli, Matthew D. Robson
Journal of the American College of Cardiology. 2016-10-18
Press Mentions
Predicting Long COVID: Who’s at Risk?March 6th, 2022- AXA1125 – a New Mitochondrial Enhancer Is Being Trialed in Long COVIDNovember 5th, 2021
- Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVIDOctober 26th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
